Tafamidis (Vyndaqel, Vyndamax) prior authorization at Geisinger Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Geisinger Health Plan requires prior-authorization documentation for Tafamidis (Vyndaqel, Vyndamax): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Geisinger Health Plan reviews Tafamidis (Vyndaqel, Vyndamax) prior authorizations against its medical policy . Geisinger Health Plan-specific context: Integrated payer-provider system in central/northeast Pennsylvania (~600K members). Acquired by Kaiser-affiliated Risant Health in March 2024 — operational integration ongoing. PA Insurance Department oversight. Strong MA presence in service area.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Geisinger Health Plan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Narrow-network denials outside Geisinger system
- Specialty referral coordination
- Medicare Advantage step therapy on Part B drugs
- Out-of-network non-emergency
Tafamidis (Vyndaqel, Vyndamax)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Genetic testing for hereditary vs wild-type ATTR not documented
- TTR-CM diagnosis not confirmed by biopsy or scintigraphy
- NYHA class IV exclusion
- Specialty pharmacy network restriction
Brand: Vyndaqel/Vyndamax. TTR stabilizer for ATTR cardiomyopathy. ATTR-ACT trial. ~$225K/year list — one of the most expensive cardiac drugs in the US.
Manufacturer patient-assistance program: Pfizer Patient Assistance — relevant when a Geisinger Health Plan denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.geisinger.org/health-plan/providers) with the same packet plus an applicable, current clinical source supporting Tafamidis (Vyndaqel, Vyndamax)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Geisinger Health Plan denial on DenialHelp.
Contact Geisinger Health Plan
- Provider portal: https://www.geisinger.org/health-plan/providers
Frequently asked questions
What documentation does Geisinger Health Plan need for Tafamidis (Vyndaqel, Vyndamax) prior auth?
Geisinger Health Plan's typical PA packet for Tafamidis (Vyndaqel, Vyndamax): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Geisinger Health Plan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Tafamidis (Vyndaqel, Vyndamax) at Geisinger Health Plan?
Preparation scenarios to check against the current notice and policy include: Narrow-network denials outside Geisinger system; Specialty referral coordination; Medicare Advantage step therapy on Part B drugs. These are not measured frequency claims. For Tafamidis (Vyndaqel, Vyndamax), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with Geisinger Health Plan on Tafamidis (Vyndaqel, Vyndamax)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Tafamidis (Vyndaqel, Vyndamax) PA packet
Open ApprovalHelp — generate a Tafamidis (Vyndaqel, Vyndamax) prior-auth packet tailored to Geisinger Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com